Nektar Therapeutics (NKTR) analyst actions
Rating and price-target actions on NKTR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NKTR overview →
8 measured NKTR analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | +0.12% | -0.81% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | +0.14% | -1.21% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out | Press release | +0.42% | +0.48% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | -0.01% | +1.10% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | +0.31% | -2.53% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out | Press release | -0.65% | +1.45% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out | Press release | +0.37% | -2.48% | |
| Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata | Press release | -1.02% | -0.84% |
Keep exploring
More NKTR: earnings → · SEC filings → · NKTR overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TROVAGENE (TROV) | 906 | -0.52% | 40% |
| KemPharm, Inc. (KMPH) | 901 | -0.21% | 40% |
| Tandem Diabetes Care, Inc. (TNDM) | 895 | +0.13% | 57% |
| Flexion Therapeutics, Inc. (FLXN) | 891 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.